Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Keros Therapeutics (KROS) Net Cash Flow (2019 - 2025)

Keros Therapeutics' Net Cash Flow history spans 7 years, with the latest figure at -$406.1 million for Q4 2025.

  • For Q4 2025, Net Cash Flow fell 1488.37% year-over-year to -$406.1 million; the TTM value through Dec 2025 reached -$272.5 million, down 218.99%, while the annual FY2025 figure was -$272.5 million, 218.99% down from the prior year.
  • Net Cash Flow reached -$406.1 million in Q4 2025 per KROS's latest filing, down from $3.3 million in the prior quarter.
  • In the past five years, Net Cash Flow ranged from a high of $160.6 million in Q1 2025 to a low of -$406.1 million in Q4 2025.
  • Average Net Cash Flow over 5 years is $1.1 million, with a median of $900500.0 recorded in 2022.
  • Peak YoY movement for Net Cash Flow: surged 5071.22% in 2023, then crashed 1488.37% in 2025.
  • A 5-year view of Net Cash Flow shows it stood at $8.7 million in 2021, then skyrocketed by 355.84% to $39.6 million in 2022, then rose by 9.17% to $43.3 million in 2023, then plummeted by 32.38% to $29.2 million in 2024, then plummeted by 1488.37% to -$406.1 million in 2025.
  • Per Business Quant, the three most recent readings for KROS's Net Cash Flow are -$406.1 million (Q4 2025), $3.3 million (Q3 2025), and -$30.3 million (Q2 2025).